Lineage Cell Therapeutics, Inc. (LCTX)
$0.91-4.21%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $227M
- Beta
- 1.60
- P/E (TTM)
- -6.48
- Short % float
- 12.30%
- Days to cover
- 15.8
- SI change
- -1.3%
- 1W
- -3.19%
- 1M
- -14.95%
- vs SPY 1W
- -3.05%
- vs SPY 1M
- -17.46%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 1
- VALUE
- 4
- GROWTH
- 19
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-42.7%
REV YoY-
ROE-71.1%
EPS YoY-
ROA-30.4%
GROSS97
OP-205
NET-247
[VALUATION]
P/E TTM-6.48
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.72
P/FCF-
EV/EBITDA-5.22
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.77
ALTMAN Z-
CURR RATIO6.61
ND/EBITDA-
BETA1.60
Company news
FAQ
- What is LOPJLB’s current signal on LCTX?
- LOPJLB’s latest quantitative signal on Lineage Cell Therapeutics, Inc. (LCTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LCTX in?
- Lineage Cell Therapeutics, Inc. (LCTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lineage Cell Therapeutics, Inc. (LCTX) do?
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an all…